Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Nobuhiko Hata
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Harmonus
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The overall goal of this research grant is to develop novel tumor localization and targeting technologies. Dr. Hata is the Lead for Project 4, the Guidance TR&D, for this grant which is focused on developing novel methods to concurrently track therapeutic tools, and motion and deformation of organs and lesions to enable Image Guided Therapy of soft and moving organs. Dr. Hata owns equity in and receives consulting income from Harmonus. Harmonus is focused on the research and development of Image Guided Therapy products. The company’s immediate project is development of MRI-guided prostate biopsy hardware and software. The institution reviewed Dr. Hata’s financial interest in connection with the research and determined that, based on the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Image Guided Therapy Center
Narrative The main challenge of tumor surgeries is to achieve the complete removal or destruction of tumors with minimal or no damage to adjacent normal tissues and their functions. There are several obstacles and limitations that prevent us to realize this vision of 'ideal precision surgery'. We propose new, innovative technological solutions for more effective and at the same time less invasive tumor treatment solutions that can provide better outcomes with much less complications than current surgical and/or interventional methods.
Filed on May 12, 2016.
Tell us what you know about Nobuhiko Hata's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Nobuhiko Hata”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Nobuhiko Hata | Brigham and Women's Hospital | Conflict of Interest | Mebio, Inc. | Value cannot be readily determined |
| Nobuhiko Hata | Brigham and Women's Hospital | Conflict of Interest | Mebio, Inc. | Value cannot be readily determined |
| Nobuhiko Hata | Brigham and Women's Hospital | Conflict of Interest | Harmonus | $60,000 - $79,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.